Imigran Injection/Subject – syringes may have needles protruding from the needle shield
- The problem
- (GlaxoSmithKline UK) Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit – class 2 action within 48 hours. (EL (13)A/26)
- What to do
- Check the batch number on your pack against the list below. Do not stop taking a prescribed medicine without talking to your pharmacist, GP or prescriber first – they can check your supply and swap it if needed.
29 October 2013
Class 2 medicines recall
Action within 48 hours
Pharmacy, wholesaler and clinic-level recall
MDR 77-10/13
Product details
Glaxo Wellcome UK Limited trading as GlaxoSmithKline UK
Imigran Injection/Subject
(Sumatriptan Succinate)
PL 10949/0113
Alert details
| Description | Batch number | Expiry date | Pack size | First distributed | ||||
|---|---|---|---|---|---|---|---|---|
| Imigran Inj/Subject Treatment | C640404 | 15 May 2015 | 2×0.5ml | 19 September 2013 | ||||
| Imigran Inj/Subject Refill | C639899 | 4 June 2015 | 2×0.5ml | 2 September 2013 | ||||
| Imigran Inj/Subject Treatment | C638748 | 4 June 2015 | 2×0.5ml | 23 August 2013 | ||||
| Imigran Inj/Subject Refill | C638737 | 4 June 2015 | 2×0.5ml | 9 September 2013 | ||||
| Imigran Inj/Subject Treatment | C636954 | 4 June 2015 | 2×0.5ml | 14 August 2013 |
Glaxo Wellcome UK Limited trading as GlaxoSmithKline UK are recalling the above batches of Imigran Injection/Subject to pharmacy, clinic and wholesaler level as a small number of syringes may have needles protruding from the needle shield.
The risk to the patient of finding an affected syringe is extremely low; the implication of patient exposure to a syringe with a protruding needle is the potential risk of infection.
Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit. For enquiries relating to stock returns please contact your original supplier.
For medical information enquiries please contact GSK on 0800 221441 or email customercontactuk@gsk.com.
Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.
Download documents
Updated 29 October 2013. This page summarises an official notice. Details can change – always follow the official notice.